Phase 1 biotech developing cell therapies for autoimmune diseases.
Industry: Health Care
Latest Trade: $5.08 -0.08 (-1.6%)
First Day Return: +36.4%
Return from IPO: -76.6%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 01/16/2024 |
Offer Price | $22.00 |
Price Range $20.00 - $21.00 | |
Offer Shares (mm) | 14.5 |
Deal Size ($mm) | $319 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 02/07/2024 |
Offer Price | $22.00 |
Price Range $20.00 - $21.00 | |
Offer Shares (mm) | 14.5 |
Deal Size ($mm) | $319 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
J.P. Morgan |
Morgan Stanley |
more |
Company Data | |
---|---|
Headquarters | Emeryville, CA, United States |
Founded | 2018 |
Employees at IPO | 84 |
Website kyvernatx.com |